Article Text
Abstract
For a significant number of patients, there exists no, or only little, interest in developing a treatment for their disease or condition. Especially with regard to rare diseases, the lack of commercial interest in drug development is a burning issue. Several interventions have been made in the regulatory field in order to address the commercial disinterest in these conditions. However, existing regulations mainly focus on the provision of incentives to the sponsors of clinical trials of orphan drugs, and leave unanswered the overarching question about the rightful place of orphan drugs in resource allocation systems. In this article, we analyse the ethical aspects of funding research and development in the field of rare diseases. We then propose an ethical framework that can help health policy makers move forward in the difficult matter of fairly allocating resources for the prevention, diagnosis and treatment of rare diseases.
- Rare diseases
- orphan drugs
- resource allocation
- ethical framework
- regulation (EC) 141/2000
- minors/parental consent
- laws and cases
- informed consent
- newborns and minors
- allocation of healthcare resources
- distributive justice
- medical ethics
- tissue engineering
- personalism
- minors in medicine
- genetic biobanking
- ethics in genetic research
- human genetics
- empirical ethics
- reproductive technology
Statistics from Altmetric.com
- Rare diseases
- orphan drugs
- resource allocation
- ethical framework
- regulation (EC) 141/2000
- minors/parental consent
- laws and cases
- informed consent
- newborns and minors
- allocation of healthcare resources
- distributive justice
- medical ethics
- tissue engineering
- personalism
- minors in medicine
- genetic biobanking
- ethics in genetic research
- human genetics
- empirical ethics
- reproductive technology
Footnotes
WP and YD contributed equally to this work.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Linked Articles
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Should rare diseases get special treatment?
- Rare neurological diseases: a practical approach to management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Ethical issues in funding orphan drug research and development
- Orphan drugs and the NHS: should we value rarity?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
- Commissioning for rare diseases: view from the frontline
- Effectiveness, safety and costs of orphan drugs: an evidence-based review